Business ❯ Pharmaceuticals ❯ Biotechnology

Gene Editing

Alpha-1 Antitrypsin Deficiency Crispr Technology

Regeneron, Tessera Strike $150 Million Gene-Editing Pact for Alpha‑1 Antitrypsin Deficiency

The one-time in vivo candidate TSRA-196 targets correction of SERPINA1 mutations, with Tessera planning an FDA filing by year-end.

AstraZeneca Licenses Algen’s AI-Guided CRISPR Discoveries in Deal Worth Up to $555 Million